Cite
P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
MLA
Sturm Andreas, et al. “P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.” American Journal of Gastroenterology, vol. 116, Dec. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e34dbff8765168cbcc3211034cf1b3c3&authtype=sso&custid=ns315887.
APA
Sturm Andreas, Sands Bruce, Wolf Douglas, D’Haens Geert, Silver Michael, Panaccione Remo, Edward V. Loftus, Pondel Marc, Petersen AnnKatrin, & Colombel Jean-Frédéric. (2021). P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. American Journal of Gastroenterology, 116.
Chicago
Sturm Andreas, Sands Bruce, Wolf Douglas, D’Haens Geert, Silver Michael, Panaccione Remo, Edward V. Loftus, Pondel Marc, Petersen AnnKatrin, and Colombel Jean-Frédéric. 2021. “P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.” American Journal of Gastroenterology 116 (December). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e34dbff8765168cbcc3211034cf1b3c3&authtype=sso&custid=ns315887.